177 related articles for article (PubMed ID: 38412388)
1. Cancer Risks Associated With
Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; ; James PA; Spurdle AB
JCO Precis Oncol; 2024 Feb; 8():e2300453. PubMed ID: 38412388
[TBL] [Abstract][Full Text] [Related]
2. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
[TBL] [Abstract][Full Text] [Related]
3. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
[TBL] [Abstract][Full Text] [Related]
5. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
6. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
7. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
[TBL] [Abstract][Full Text] [Related]
8. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
Fortuno C; James PA; Spurdle AB
Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
[TBL] [Abstract][Full Text] [Related]
9. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
[TBL] [Abstract][Full Text] [Related]
10. Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts.
Shin SJ; Dodd-Eaton EB; Peng G; Bojadzieva J; Chen J; Amos CI; Frone MN; Khincha PP; Mai PL; Savage SA; Ballinger ML; Thomas DM; Yuan Y; Strong LC; Wang W
Cancer Res; 2020 Jan; 80(2):354-360. PubMed ID: 31719101
[TBL] [Abstract][Full Text] [Related]
11. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
[TBL] [Abstract][Full Text] [Related]
12. Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective.
Shin SJ; Dodd-Eaton EB; Gao F; Bojadzieva J; Chen J; Kong X; Amos CI; Ning J; Strong LC; Wang W
Cancer Res; 2020 Jan; 80(2):347-353. PubMed ID: 31719099
[TBL] [Abstract][Full Text] [Related]
13. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
[TBL] [Abstract][Full Text] [Related]
15. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
16. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
17. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
18. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
19. Next generation sequencing is informing phenotype: a TP53 example.
O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
